SNIPR Biome ApS

DUBLIN--( BUSINESS WIRE )--The "Sepsis - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 30+ companies and 35+ pipeline drugs in Sepsis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sepsis pipeline landscape is provided which includes the disease overview and Sepsis treatment guidelines. The assessment part of the report embraces, in depth Sepsis commercial assessment and clinical assessment of the pipeline products under development In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sepsis collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Sepsis R&D. The therapies under development are focused on novel approaches to treat/improve Sepsis. Sepsis Emerging Drugs Chapters This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. Sepsis Emerging Drugs Thymosin alpha 1: SciClone Pharmaceuticals Thymosin alpha 1, referred to as thymalfasin, is a synthetic 28-amino acid peptide with multiple biological activities primarily directed towards immune response enhancement. SciClone developed and launched Thymosin alpha 1, under the trade name Zadaxin, for the treatment of hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infections. The drug is also being developed for the treatment of COVID 2019 infections. Scientific and clinical studies have shown that Thymosin alpha 1 helps to stimulate and direct the body's immune response to eradicate infectious diseases, such as HBV, HCV, bacterial, and fungal infections; to fight certain cancers such as melanoma and liver cancer; and to enhance response to vaccines. Clinical trials have shown that Thymosin alpha 1 improves survival in patients in intensive care units being treated for sepsis from severe bacterial infections. The therapy is being evaluated in Phase III stage to treat Sepsis. Currently, the drug is in Phase III stage of its development for the treatment of sepsis. Enibarcimab: AdrenoMed AG Enibarcimab (HAM8101; former name: Adrecizumab) a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Enibarcimab is supported by the elegance of its mode of action, a monoclonal antibody that on binding to its target Adrenomedullin preserves its functionality as regulator of vascular integrity. Enibarcimab targets Adrenomedullin (ADM), a vasoprotective peptide hormone. ADM that remains in the bloodstream, however, has a different effect, one that helps mitigate sepsis: promoting stability of the endothelial barrier by restoring the cell junctions between endothelial cells that ordinarily regulate molecule transport and leakage. In health, levels of ADM in the bloodstream and extravascular space are in equilibrium so that endothelial barrier integrity is maintained and blood pressure remains normal. Currently, the drug is in Phase II stage of its development for the treatment of sepsis. M 6229: Matisse Pharmaceuticals Matisse's platform technology is based on the discovery that in many patients suffering from sepsis, proteins called histones are released by the innate immune system and dying cells into the blood stream, where they are toxic to other cells. Due to a self-enforcing cascade, people may die from organ failure within one or two days. Preclinical results have shown that by neutralizing the toxic histones with Matisse's product M6229, the negative cascade is terminated by neutralization of cationic histones by anionic M6229. Matisse claims to have identified an elegant solution for treating one of the major complications in sepsis by using a non-anticoagulant fraction of heparin called M6229 to neutralize toxic circulatory histones .Currently, the drug is in Phase I stage of its development for the treatment of sepsis. SNIPR 001: SNIPR Biome SNIPR001 is a novel, orally-administered antibiotic that is designed to precisely target difficult-to-treat bacterial infections. It is developed using SNIPR Biome's CRISPR-Guided VectorsT (CGVT Technology), which is designed to deliver CRISPR reagents into target bacterial cells. SNIPR001 is designed to target certain E. coli bacteria in the gut and thus prevent their translocation to the bloodstream, without affecting beneficial bacteria in the microbiome. It contains four CRISPR-armed phages that selectively target and eliminate E. coli strains that are resistant to fluoroquinolone, with demonstrated efficacy in animal disease models. Currently, the drug is in preclinical stage of its development for the treatment of sepsis. Sepsis: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sepsis therapeutic drugs key players involved in developing key drugs. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sepsis drugs. Sepsis: Therapeutic Assessment Phases Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of Administration Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Molecule Type Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Product Type Sepsis Report Insights Sepsis Pipeline Analysis Therapeutic Assessment Unmet Needs Impact of Drugs Sepsis Report Assessment Pipeline Product Profiles Therapeutic Assessment Pipeline Assessment Inactive drugs assessment Unmet Needs Key Players SciClone Pharmaceuticals AdrenoMed AG Matisse Pharmaceuticals SNIPR Biome Tianjin Chase Sun Pharmaceutical Beijing Scitech-Mq Pharmaceuticals Recce Pharmaceuticals Inotrem Octapharma Shaperon Shionogi Pharmazz Seres Therapeutics Key Products Thymosin alpha 1 Enibarcimab M 6229 SNIPR 001 Kukoamine B ST-1830 RECCE 327 Nangibotide OctaplasLG HY209 Cefiderocol Centhaquine SER 155 For more information about this clinical trials report visit https://www.researchandmarkets.com/r/ixi7k5 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sensei Bio Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer. Ms. Krebs joins Sensei from SNIPR Biome, a clinical-stage biotechnology company where, as Chief Business Officer, she was responsible for defining the company’s growth and partnering activities, including value creation through collaborations with large pharmaceutical and biotech partners. Prior to this, she held business and corporate development roles of increasing responsibility in a number of companies, including Valo Health, bluebird bio, HotSpot Therapeutics and Swedish Orphan Biovitrum (Sobi) AB. Ms. Krebs also spent 10 years at Biogen, where she initially supported commercial activities before moving into business development and focused on generating strategic partnerships for the company’s neurology and immunology pipelines. Ms. Krebs holds an MS in biotechnology from Johns Hopkins University and an MBA from the University of Rochester. “We’re delighted to welcome Stephanie to our leadership team at such an exciting moment for Sensei, as we advance the ongoing Phase 1/2 clinical trial of our lead candidate SNS-101 and prepare to move an additional candidate toward IND-enabling studies,” said John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics. “She has a track record of driving strategic alliances that move novel medicines closer to patients while providing fuel for continued pipeline expansion and program development. Her business development expertise and deep understanding of the drug development landscape are critical to executing on our near-term strategic initiatives while planning thoughtfully for the future.” “Sensei is facing head-on the challenges that have limited innovation in immuno-oncology and has assembled a skilled and highly motivated team,” said Ms. Krebs. “I look forward to joining the team at this exciting stage and leveraging my experience to contribute to the company’s continued progress and growth.” About Sensei Biotherapeutics: Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39.  For more information, please visit  , and follow the company on Twitter @SenseiBio and LinkedIn. Cautionary Note Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “believe”, “designed to,” “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Sensei’s current beliefs and expectations. These forward-looking statements include expectations regarding the development and potential therapeutic benefits of Sensei’s product candidates, the timing of Sensei’s Phase 1/2 clinical trial of SNS-101, including reporting of data therefrom, and the timing of selection of product candidates and IND-enabling studies. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as the risk that any one or more of Sensei’s product candidates will not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Sensei’s product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Sensei’s product candidates; the risk that Sensei’s product candidates or procedures in connection with the administration thereof will not have the safety or efficacy pro we anticipate; risks associated with Sensei’s dependence on third-party suppliers and manufacturers, including sole source suppliers, over which we may not always have full control; risks regarding the accuracy of our estimates of expenses, capital requirements and needs for additional financing; and other risks and uncertainties that are described in Sensei’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on or about August 3, 2023 and Sensei’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Sensei as of the date of this release, and Sensei assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Contact: Michael Biega Senior Director, Investor Relations Sensei Biotherapeutics mbiega@senseibio.com Media Contact: Chris Railey Ten Bridge Communications chris@tenbridgecommunications.com

None   Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week.  Madrigal snags Sanofi's Bill Sibold as CEO Madrigal Pharmaceuticals Sanofi’s Bill Sibold has left after a 12-year run, departing for Madrigal Pharmaceuticals, where he is taking the top spot.   Sibold most recently served as Sanofi’s executive vice president of specialty care and president of North American operations. In those roles, he oversaw 10,000 staffers and grew his operations into the pharma’s largest global business unit. The Big Pharma’s current head of specialty care in North America, Brian Foard, has assumed Sibold’s post while the company searches for a permanent successor.  At Madrigal, Sibold takes the reins from Paul Friedman, M.D., who has helmed the organization for seven years. The CEO change-up comes as the organization gears up for a potential FDA green light for lead candidate resmetirom, which would be the first nonalcoholic steatohepatitis treatment to make it to market if approved. The FDA has given resmetirom priority review and expects to make a decision by March 14, 2024. Fierce Biotech  Jazz changes octaves with COO swap Jazz Pharmaceuticals Jazz Pharmaceuticals is singing a new executive tune, after President and Chief Operating Officer Dan Swisher decided to move on from the company. Taking his place is Chief Financial Officer Renée Galá, who’s being fully promoted after joining the company in 2020. She’s previously worked at Theravance, Grail and Lilly.  The changing of the guards comes as Jazz’s pipeline is in the midst of its own transition. Sales of narcolepsy drug Xyrem are being crunched as generics enter the fold, but low-sodium alternative Xywav raked in $327 million in sales in the second quarter. Additional marketed meds Epidiolex and Rylaze each had double-digit growth in the second quarter compared to the same period in 2022.  Beyond just betting on its existing portfolio, Jazz is hunting for additional deals, according to CEO Bruce Cozadd. He told Fierce Biotech in June that the company was on the hunt for deals involving neurology and oncology treatments. Fierce Pharma  Amanda Kay to oversee business development at Flagship Flagship Pioneering Some four months ago, Amanda Kay was hired as president of new Flagship spinout Metaphore Biotechnologies. Now, she’s taking on a significantly larger role, leading business development for the whole firm as chief business development partner. She’s also being promoted from operating partner to senior partner. A spokesperson confirmed that she’s relinquished her role at Metaphore as part of move. Before joining the Flagship ecosystem, Kay was the chief business officer and head of finance at Deep Genomics. She was also the head of corporate development at Synlogic and was the chief operating officer for Pfizer’s inflammation and immunology research units. The CEO of Metaphore, Lovisa Afzelius, Ph.D., overlapped with Kay at Pfizer.  Needless to say, business development is a crucial staple of drug development across the industry but especially at Flagship. Companies like Generate Biomedicines, Moderna and Foghorn, to name a few, all have made considerable licensing and/or research pacts since launching. Release  > Sling Therapeutics has tapped Raymond Douglas, M.D., Ph.D., to serve as chief scientific officer. Douglas' research contributed to the development of Horizon Therapeutics' Tepezza, the first and only FDA-approved treatment for thyroid eye disease. Release > Mitchell Jones, M.D., Ph.D., is joining Palisade Bio as chief medical officer. He previously was the VP of corporate development and strategy at Chemomab Therapeutics. Release > LIB Therapeutics co-founder and CEO Evan Stein, M.D., Ph.D., is transitioning out of the top leadership role but taking on CSO and COO duties. Replacing him as CEO is David Cory, former CEO of Eiger BioPharmaceuticals. Release > SpringWorks Therapeutics hopes a new scientific chief can help propel forward the company’s research ambitions, naming Tai-An Lin, Ph.D., for the role. Lin previously oversaw translational research and discovery biology at Black Diamond Therapeutics. Release > Philip Vickers, Ph.D., has been tapped as the new CEO and president of Solu Therapeutics. He most recently was the CEO of Faze Medicines and also sits on the board of AVROBIO. Release > Pliant Therapeutics is welcoming on Minnie Kuo as chief development officer. Before Pliant, Kuo held roles of increasing responsibilities at Vir Biotechnology, most recently serving as SVP of translational and clinical development operations. Release > German biotech Repairon has chosen executive chair and co-founder Lothar Germeroth, Ph.D., to helm the company. Germeroth, also a major shareholder of Repairon, is a biochemist and serial biotech entrepreneur. Release > Confo Therapeutics has chosen Stephen Dowd, Ph.D., as its chief business officer. Dowd joins the GPCR company from Rallybio, where he served as head of business development for European operations, and also has past experience at Kymab (acquired by Sanofi), SNIPR Biome and GSK. Release > Jacob Jacobsen, Ph.D., is succeeding Joseph Patti, Ph.D., as Evecxia Therapeutics’ president and CEO. Patti has stepped down to pursue other interests, while Jacobsen joins from Duke University and Duke-National University Singapore, where he conducted research. Release > Innate Pharma is bringing on Sonia Quaratino, M.D., Ph.D., as EVP and chief medical officer starting in October. Quaratino succeeds Joyson Karakunnel, M.D., and has previously held positions at Georgiamune, Kymab (acquired by Sanofi), Novartis and Merck Serono (Merck KGaA). Release > Belgium biotech Augustine Therapeutics is growing its team with three new additions: Marie Trad, M.D., as chief medical officer; Jonathan van Eyll, Ph.D., as head of pharmacology; and Cédric Szyndralewiez as head of nonclinical and early development. Trad is a neurologist and founder of Neuraltra, while von Eyll helped establish UCB Pharma’s translational bioinformatics unit and Szyndralewiez has more than 25 years of drug research and development, most recently from Pherecydes Pharma. Release > Myricx Bio has tapped Dr. Robert McLeod as VP of clinical development. McLeod joins the U.K. biotech having previously served as Daiichi Sankyo’s senior director and global clinical lead, a research physician at Cancer Research UK's Center for Drug Development and various roles at Emergent BioSolutions, Novartis and Chiron. Release > Biostax’s Immune Therapeutics CEO Kelly Wilson and President and Director Robert Wilson both resigned July 25, departures that were not due to any dispute or disagreement relating to the company, according to Securities and Exchange Commission documents. The board immediately appointed Immune Therapeutics’ VP Noreen Griffin to serve as CEO. Release > Spine and orthopedics company Orthofix has ousted its President and CEO Keith Valentine, Chief Financial Officer John Bostjancic and Chief Legal Officer Patrick Keran after the board of directors “determined that each of these executives engaged in repeated inappropriate and offensive conduct that violated multiple code of conduct requirements and was inconsistent with the company’s values and culture.” Effective immediately, Orthofix’s board chair Catherine Burzik is taking on the CEO spot. Fierce Medtech > 4D Molecular Therapeutics has appointed Uneek Mehra as chief financial and business officer, succeeding August Moretti in his retirement. Mehra joins from Myovant Sciences (acquired by Sumitovant Biopharma), where he also served as CFO and CBO, and also held a senior leadership role at Novartis among other companies. Release > Oculis is welcoming Rebecca Weil, Ph.D., to serve as the eye care company’s chief commercial officer. Before Oculis, Weil was Idorsia’s VP and head of global marketing. Release